10 (2) 14 (5) LV septal thickness (mm) 10 17 (5) 19 (4) 22 (7) 11 (1) 20 (6) LV septal:PW thickness ratio
24 (4) 25 (7) 21 (6) 30 (5) 23 (5) Septum to mitral valve (mm) at onset of systole 28 23 (4) 26 (5) 21 (2) 26 (3) 22 (7) SAM (%) Table 2 shows biochemical data for all 22 patients presenting with hypercalcaemia. There were two groups of patients: those in whom parathyroid hormone concentration was raised and those in whom it Parathyroid hormone has a positive chronotropic effect on myocardial cells in culture and its action is mimicked by calcium ionophore and blocked by verapamil." In hamsters with congenital myopathy there was an increase in intracellular calcium concentrations in skeletal muscle; after parathyroidectomy the intracellular calcium concentration fell and myopathy improved.8 Parathyroid hormone has also been shown to have a positive inotropic effect on the rat heart at physiological concentrations.9 Since this action is also blocked by verapamil, it must be directly related to the movement of calcium into the myocardial cell. These experimental data indicate that parathyroid hormone has a direct effect on the myocardium which is mediated by an influx of calcium. Such positive chronotropic and inotropic effects are consistent with the possibility that in the long term the maintenance of high concentrations of parathyroid hormone may result in cardiac hypertrophy. Hypertrophy and disarray of the cardiac muscle fibril, identical to that seen in hypertropic cardiomyopathy, has been produced experimentally by substances which disturb membrane stability, such as triac and calcium ionophore,210 and parathyroid hormone could act in a similar way. The time that has elapsed since some of our patients had parathyroidectomy is not sufficient to assess whether myocardial hypertrophy has regressed. Clinical evidence suggests that improvement will occur." Experiments aimed at investigating the structure and function of the myocardium using a parathyroid hormone stimulus are underway in our laboratory and are designed to define both the mode of action of the hormone and to build a model of increasing ventricular hypertrophy.
Our data indicate that all patients with hyperparathyroidism should be examined by echocardiography so that the presence of myocardial hypertrophy will not be missed. Conversely, serum concentrations of parathyroid hormone should be measured in all patients with left ventricular hypertrophy from an unknown cause, (especially those with hypertrophic cardiomyopathy) so that any parathyroid abnormality can be treated. Most of our patients with raised serum parathyroid hormone concentrations had normal electrocardiograms and none was hypertensive. Females predominated in the present series and this may be because of the small numbers of patients studied.
In conclusion, an association between cardiac hypertrophy (symmetric, asymmetric, and hypertrophic cardiomyopathy) and an increased concentration of parathyroid hormone has been demonstrated that is independent of hypercalcaemia. For the first time a pattern of cardiac muscle hypertrophy clearly related to an hormonal abnormality has been shown to occur. This adds another dimension to the understanding of a possible cause of idiopathic ventricular hypertrophy and even suggests that hypertrophic cardiomyopathy could be one form of end stage exuberant cardiac muscle hypertrophy. Further elucidation of the role and nature of parathyroid hormone in relation to ventricular hypertrophy and of a causal link between hyperparathyroidism and all forms of ventricular hypertrophy, including hypertrophic cardiomyopathy, is awaited. 
